Champions Oncology, Inc. announced an agreement to adopt BioVolume's 3D imaging and thermal technology as their primary means of capturing efficacy results. Through this multi-year agreement Champions Oncology will incorporate BioVolume's thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings. In alignment with Champions consistent focus on delivering the highest quality data and scientific excellence, the adoption of BioVolume technology will enable achievement of greater accuracy, reduced variability, and the generation of reliable insights to advance oncology drug development programs across different therapeutic modalities.

BioVolume is advancing global preclinical oncology by providing greater study accuracy and helping strengthen drug filings for clinical trials with a digital record of preclinical efficacy. Specifically, BioVolume detects, segments, and measures subcutaneous tumor growth in rodents. By providing traceable imaging for each volume measurement alongside the additional capture of tumor height, it ensures greater reproducibility of study data and offers a statistically significant reduction in variability compared to calipers which rely on manual measurement.

In silico modelling of BioVolume data demonstrates that reducing variability can decrease the chance of missing a therapeutic effect by a factor of seven in comparison to existing caliper-based processes.